Vemurafenib and dabrafenib are BRAF inhibitors approved by the US Food and Drug Administration for treating metastatic melanoma, especially for patients harboring distant metastases with BRAF mutations [6]. The gene discussed is BRAF; the disease is metastatic melanoma.